
- Shenzhen Wenzhi Bio-Technology Co.,Ltd
- Shenzhen Wenzhi Bio-Technology Co.,Ltd Professional Supplier of Raw steroid powder & injectable & o
Home>Products>Weight Loss Steroids>Legal Weight Loss Steroids Body Slim Lorcaserin Hydrochloride ISO9001 Approved

Legal Weight Loss Steroids Body Slim Lorcaserin Hydrochloride ISO9001 Approved
- HW Weight Loss Steroids
Weight Loss Steroids
- China
- GMP,SGS,UKAS,ISO
- Negotiable
- Negotiable
- foil bag or as your requirement
- 6 hours after receiving payment
- T/T, Western union, MoneyGram
- 1000kgs/month
-
Shenzhen Wenzhi Bio-Technology Co.,Ltd2020-07-10 09:46:19
Welcome to my shop! Glad to serve you! Please send your question!
Product Details
Molecular Formula: | C11H14ClN?ClH | Molecular Weight: | 232.1525 | CAS: | 846589-98-8 |
Assay: | 99% | Appearance: | White powder | Keywords: | Weight Loss Steroids,Pentadecapeptide Peptide Bpc157 Steroid, Peptide Lyophilized Steroid, Purity Peptide Steroid, Orlistat Steroid, Steroid Hormone, Weight Loss Triiodothyronine, Weight Loss Thyroxine ,Steroid Powder Orlistat, Weight Loss Hydroxytryptopha |
Product Description
Body Weight Loss Steroids Slim Lorcaserin Hydrochloride Legal Steroids For Weight Loss
Basic Information
Item | Specification |
CAS | 846589-98-8 |
Formula | C11H14ClN?ClH |
Molecular Weight | 232.1525 |
EINECS | N/A |
Assay | 99% |
Description
Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
Medical uses
Lorcaserin is used long term for weight loss in those who are obese.
Adverse effects
In clinical trials, the most common side effect was headache, experienced by about 18% of drug arm participants compared to 11% of placebo participants. Headache was the only reported side effect to occur at a frequency greater than 5 percentage points above those from placebo. Other reported side effects and their rates for lorcaserin and placebo patients, respectively, were as follows: upper respiratory tract infection (14.8% vs. 11.9%), nasopharyngitis (13.4% vs. 12.0%), sinusitis (7.2% vs. 8.2%), and nausea (7.5% vs. 5.4%). Adverse events of depression, anxiety, and suicidal ideation were infrequent and were reported at a similar rate in each treatment group.
On 15 September 2010 it was reported by national news media that lorcaserin was associated with the development of cancer in laboratory rats.
In December 2012, the US Drug Enforcement Administration proposed classifying lorcaserin as a Schedule IV drug because it has hallucinogenic properties at higher than approved doses and users could develop psychiatric dependencies on the drug. On 7 May 2013, the US Drug Enforcement Administration classified lorcaserin as a Schedule IV drug under the Controlled Substances Act.
There has been concern that lorcaserin can cause cardiac valvulopathy based upon the reports of subjects taking the drug in Phase 2 trials. However, a Phase 3 clinical trial of the drug was conducted and the results published in the October 2014 Postgraduate Medicine journal, a peer-reviewed medical journal for physicians. These results found no statistically significant differences in valvulopathy rates compared to control, being 2.4% for the drug subjects and 2.0% for controls.
Mechanism of action
Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor.
Approval history
On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted to recommend against approval of the drug based on concerns over both safety and efficacy.In October 2010, the FDA stated that it could not approve the application for lorcaserin in its present form.
Lorcaserin had a Prescription Drug User Fee Act (PDUFA) date of 22 October 2010. On 16 September 2010, a federal advisory committee voted against recommending approval for lorcaserin. In their 9-5 vote, the committee raised concerns about the safety of the drug, particularly the findings of tumors in rats. On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered "marginal."
After additional studies were completed and additional information submitted to the FDA, an advisory panel was convened on 10 May 2012. The advisory panel voted 19-4-1 to recommend lorcaserin to the FDA. The FDA stated that the weight loss data passed FDA standards for efficacy and that the drug did not have cancer risks based on clarifications in the data. The FDA panelist recommended that postmarketing studies regarding potential heart valve issues be completed. The FDA has not stated one way or the other whether they believe this is necessary at this time although no related safety markers have been indicated during clinical studies.[citation needed] On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for some adults.
On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes. On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol."
Proceeding your order
- Describing items you are favorable, quantities, and the destination country
- Confirming all details, and placing order.
- Receiving the quotation we send and transportation recommended
- Paying for the order, informing us the detailed contact information, including contact person/company, address, mobile number, ZIP code and special requirements.
- Notice cargo shipping usually happens after receiving payment a day later, but we will inform you the detailed arrangement and track the goods all the time.
- Contacting us for any problems or troubles in terms of quality and functions at any time. Your feedback will be highly appreciated!
Our Privileges
High quality with competitive price
- Standard: Enterprise Standard
- All Purity≥99%
- We are manufacturer and can provide high quality products with factory price
Fast and safe delivery
- Parcel can be sent out in 24 hours after payment. Tracking number available
- Secure and discreet shipment. Various transportation methods for your choice
- Customs pass rate ≥99%
- We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock for transferring
Clients throughout the world
- Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
- Market feedback and goods feedback will be appreciated, meeting customerss requirement is our responsibility.
- High quality,competitive price,fast delivery ,first-class service gain the trust and praise from customers.
If you are interested in our products, please feel free to contact me.
![]() |
Legal Weight Loss Steroids Body Slim Lorcaserin Hydrochloride ISO9001 Approved Images |
Contact Us

- Shenzhen Wenzhi Bio-Technology Co.,Ltd
- Address
- Phone(Working Time)
- Fax
Product Categories
- Injectable Anabolic Steroids
- Testosterone Steroid
- Boldenone Steroid
- Trenbolone Steroid
- Masteron Steroid
- Primobolan Steroid
- Oral Anabolic Steroids
- Steroid Hormones Powder
- Prohormones Steroids
- Female Steroids
- Male Enhancement Steroids
- Weight Loss Steroids
- Anti Inflammatory Steroids
- Local Anesthetic Agents
- SARMS Raw Powder
- Organic Solvents
- Polypeptide Hormone
- Pharmaceutical Raw Material
- Anti Estrogen Steroids
- Nandrolone Steroid
New Products
99% High Purity Weight Loss Steroids Raw Steroid For Fat Loss Orlistat White
White Powder Natural Weight Loss Steroids Supplements Calcium Pyruvate CAS 52009
White Powder Prohormone Furazabol Thp For Bodybuilding CAS 1239-29-8
CAS 1239-29-8 Weight Loss Steroids Prohormone Furazabol Thp For Bodybuilding
98% Purity L-Carnitine Weight Loss Steroids For Cutting Fat 541-15-1